The emergence of strains resistant to ceftazidime/avibactam (CAZ/AVI) has recently been reported [1,2]. Furthermore, an increase in cefiderocol (CFD) minimum inhibitory concentration (MIC) values has been observed in Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriales cross-resistant to CAZ/AVI [3]. In this study, we reported the development of resistance to CAZ/AVI and CFD in Klebsiella pneumoniae strains carrying the novel variant blaCMY-186 isolated from a single patient during antimicrobial exposure.
Amadesi S., Gatti M., Rinaldi M., Pea F., Viale P., Gaibani P. (2024). Novel CMY-186 variant conferring cross-resistance to cefiderocol and ceftazidime/avibactam in Klebsiella pneumoniae from a critically ill patient during cefiderocol and ceftazidime/avibactam treatment. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 63(4), 1-2 [10.1016/j.ijantimicag.2024.107107].
Novel CMY-186 variant conferring cross-resistance to cefiderocol and ceftazidime/avibactam in Klebsiella pneumoniae from a critically ill patient during cefiderocol and ceftazidime/avibactam treatment
Gatti M.;Rinaldi M.;Pea F.;Viale P.;Gaibani P.
2024
Abstract
The emergence of strains resistant to ceftazidime/avibactam (CAZ/AVI) has recently been reported [1,2]. Furthermore, an increase in cefiderocol (CFD) minimum inhibitory concentration (MIC) values has been observed in Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriales cross-resistant to CAZ/AVI [3]. In this study, we reported the development of resistance to CAZ/AVI and CFD in Klebsiella pneumoniae strains carrying the novel variant blaCMY-186 isolated from a single patient during antimicrobial exposure.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
